Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb 14;5(1):8.
doi: 10.3390/geriatrics5010008.

Phenotypes of Sarcopenic Obesity: Exploring the Effects on Peri-Muscular Fat, the Obesity Paradox, Hormone-Related Responses and the Clinical Implications

Affiliations
Review

Phenotypes of Sarcopenic Obesity: Exploring the Effects on Peri-Muscular Fat, the Obesity Paradox, Hormone-Related Responses and the Clinical Implications

Tariq A Alalwan. Geriatrics (Basel). .

Abstract

Sarcopenic obesity combines the words sarcopenia and obesity. This definition of obesity should be better differentiated between visceral and subcutaneous fat phenotypes. For this reason, this review lays the foundation for defining the subcutaneous and the visceral fat into the context of sarcopenia. Thus, the review aims to explore the missing links on pathogenesis of visceral fat and its relationship on age: defining the peri-muscular fat as a new entity and the subcutaneous fat as a first factor that leads to the obesity paradox. Last but not least, this review underlines and motivates the mechanisms of the hormonal responses and anti-inflammatory adipokines responsible for the clinical implications of sarcopenic visceral obesity, describing factor by factor the multiple axis between the visceral fat-sarcopenia and all mortality outcomes linked to cancer, diabetes, cardiovascular diseases, cirrhosis, polycystic ovary, disability and postoperative complications.

Keywords: inflammation; obesity; sarcopenia; subcutaneous fat; visceral fat.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Similar articles

Cited by

References

    1. Perna S., Spadaccini D., Rondanelli M. Sarcopenic obesity: Time to target the phenotypes. J. Cachexia Sarcopenia Muscle. 2019;10:710–711. doi: 10.1002/jcsm.12425. - DOI - PMC - PubMed
    1. Neeland I.J., Ross R., Després J.P., Matsuzawa Y., Yamashita S., Shai I., Seidell J., Magni P., Santos R.D., Arsenault B., et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: A position statement. Lancet Diabetes Endocrinol. 2019;7:715–725. doi: 10.1016/S2213-8587(19)30084-1. - DOI - PubMed
    1. Prado C.M.M., Wells J.C.K., Smith S.R., Stephan B.C.M., Siervo M. Sarcopenic obesity: A Critical appraisal of the current evidence. Clin. Nutr. 2012;31:583–601. doi: 10.1016/j.clnu.2012.06.010. - DOI - PubMed
    1. Perna S., Spadaccini D., Nichetti M., Avanzato I., Faliva M.A., Rondanelli M. Osteosarcopenic Visceral Obesity and Osteosarcopenic Subcutaneous Obesity, Two New Phenotypes of Sarcopenia: Prevalence, Metabolic Profile, and Risk Factors. J. Aging Res. 2018;2018:1–8. doi: 10.1155/2018/6147426. - DOI - PMC - PubMed
    1. Zamboni M., Mazzali G., Fantin F., Rossi A., Di Francesco V. Sarcopenic obesity: A new category of obesity in the elderly. Nutr. Metab. Cardiovasc. Dis. 2008;18:388–395. doi: 10.1016/j.numecd.2007.10.002. - DOI - PubMed

LinkOut - more resources